Publications Database

Accordino R. E. et al. (2016)

Psychopharmacological interventions in autism spectrum disorder.

Expert Opinion on Pharmacotherapy

May, 17(7), pp. 937-952.

Read Abstract (New Window)

Alderton H. (1970)

Imipramine in childhood nocturnal enuresis: relationship of time of administration to effect.

Canadian Psychiatric Association Journal

102 pp. 197-203

Read Full (New Window)

Aman M. G. (2004)

Management of hyperactivity and other acting-out problems in patients with autism spectrum disorder.

Seminars in Pediatric Neurology

11(3), pp. 225-228

Read Abstract (New Window)

Aman M. G. et al. (1986)

Preliminary study of imipramine in profoundly retarded residents.

Journal of Autism and Developmental Disorders

16(3), pp. 263-273.

Read Abstract (New Window)

Aman M. G. , Hollway J. A. , Arnold L. E. (2008)

Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders.

Child and Adolescent Psychiatric Clinics of North America

17(4), pp. 713-738

Read Abstract (New Window)

Anagnostou E. et al. (2006)

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder.

Journal of Clinical Psychopharmacology

26(4), pp. 444-446

Anagnostou E. , Hansen R. L. (2011)

Medical treatment overview: traditional and novel psycho-pharmacological and complementary and alternative medications.

Current Opinions in Pediatrics

23(6), pp. 621-627.

Read Abstract (New Window)

Awad G. A. (1996)

The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders: some clinical observations.

Canadian Journal of Psychiatry

August, 41(6), pp. 361-366

Read Abstract (New Window)

Bachmann C. J. et al. (2013)

Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany.

Research in Developmental Disabilities

June, 34(9), pp. 2551-2563.

Read Abstract (New Window)

Baribeau D. A. , Anagnostou E. (2014)

An update on medication management of behavioral disorders in autism.

Current Psychiatry Reports

16(3), pp. 437

Read Abstract (New Window)

Bates G. , Willson S. W. (2003)

'Use of selective serotonin reuptake inhibitors in children with pervasive developmental disorder: risk of treatment emergent mania'.

Developmental Medicine and Child Neurology

45(5), p.359; author reply p.360

Benvenuto A. et al. (2013)

Pharmacotherapy of autism spectrum disorder.

Brain and Development

35(2), pp. 119-127.

Read Abstract (New Window)

Bethea T. C. , Sikich L. (2007)

Early pharmacological treatment of autism: a rationale for developmental treatment.

Biological Psychiatry

61(4), pp. 521-537

Read Abstract (New Window) Read Full (New Window)

Bhardwaj A. , Agarwal V. , Sitholey P. (2005)

Asperger's disorder with co-morbid separation anxiety disorder: A case report.

Journal of Autism and Developmental Disorders

35(1), pp. 135-136

Bhatti I. et al. (2013)

A retrospective study of amitriptyline in youth with autism spectrum disorders.

Journal of Autism and Developmental Disorders

43(5), pp. 1017-1027.

Read Abstract (New Window)

Bishop J. R. et al. (2015)

Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Pharmacogenetics and Genomics

November, 25(11), pp. 548-554.

Read Abstract (New Window)

Boyd K. , Woodbury-Smith M. R. , Szatmari P. (2011)

Managing anxiety and depressive symptoms in adults with autism-spectrum disorders.

Journal of Psychiatry and Neuroscience

36(4), E 35-36

Read Full (New Window)

Brasić J. R. (1994)

Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation

Neurology

44(7), pp. 1309-1312

Read Abstract (New Window)

Brasić J. R. (1997)

Dyskinesias subside off all medication in a boy with autistic disorder and severe mental retardation.

Psychology Report

81(3), pp. 755-767

Read Abstract (New Window)

Brodkin E. (1997)

Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.

Journal of Child and Adolescent Psychopharmacology

7(2), pp. 109-121

Read Abstract (New Window)